We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-0.78%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$357M
AUM Growth
-$64.5M
Cap. Flow
-$58.5M
Cap. Flow %
-16.36%
Top 10 Hldgs %
65.85%
Holding
90
New
23
Increased
14
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$9.89M
2
IMMU
Immunomedics Inc
IMMU
+$7.7M
3
KITE
Kite Pharma, Inc.
KITE
+$6.12M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$3.75M
5
ARGX icon
argenx
ARGX
+$3.18M

Top Sells

Rank Stock Value
1
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$9.77M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.62M
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$5.98M
4
MRVL icon
Marvell Technology
MRVL
+$5.34M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.58M

Sector Composition

Rank Sector Weight
1 Healthcare 60.37%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$52B
$3.24M 0.91%
+152,837
New +$3.18M
ACRS icon
27
Aclaris Therapeutics
ACRS
$772M
$2.44M 0.68%
90,000
-110,000
-55% -$2.99M
JUNO
28
PUT
DELISTED
Juno Therapeutics, Inc.
JUNO
$2.39M 0.67%
+80,000
New +$1.97M
IOVA icon
29
CALL
Iovance Biotherapeutics
IOVA
$1.93B
$2.38M 0.67%
324,000
+284,000
+710% +$1.81M
INDP icon
30
Indaptus Therapeutics
INDP
$175M
$2.28M 0.64%
+179
New +$2.17M
NDRM
31
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.18M 0.61%
72,866
-377,134
-84% -$9.77M
AERI
32
PUT
DELISTED
Aerie Pharmaceuticals
AERI
$2.1M 0.59%
+40,000
New +$1.86M
WBMD
33
DELISTED
WebMD Health Corp.
WBMD
$1.94M 0.54%
+33,000
New +$1.84M
CLVS
34
DELISTED
Clovis Oncology, Inc.
CLVS
$1.87M 0.52%
20,000
-20,361
-50% -$1.25M
LCI
35
PUT
DELISTED
Lannett Company, Inc.
LCI
$1.83M 0.51%
+22,400
New +$1.95M
EXEL icon
36
PUT
Exelixis
EXEL
$13.8B
$1.72M 0.48%
+70,000
New +$1.48M
SPNC
37
PUT
DELISTED
Spectranetics Corp
SPNC
$1.54M 0.43%
+40,000
New +$1.15M
ZGNX
38
PUT
DELISTED
Zogenix, Inc.
ZGNX
$1.45M 0.41%
100,000
– –
SCTL
39
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.41M 0.39%
+223,558
New +$1.53M
ALIM
40
DELISTED
Alimera Sciences
ALIM
$1.35M 0.38%
64,955
– –
VCYT icon
41
CALL
Veracyte
VCYT
$3.58B
$1.33M 0.37%
160,000
+30,000
+23% +$245K
GKOS icon
42
PUT
Glaukos
GKOS
$10.1B
$999K 0.28%
+24,100
New +$1.04M
NVTA
43
DELISTED
Invitae Corporation
NVTA
$959K 0.27%
+100,292
New +$990K
BCRX icon
44
BioCryst Pharmaceuticals
BCRX
$2.24B
$938K 0.26%
168,685
-751,625
-82% -$4.58M
TCRT icon
45
PUT
Alaunos Therapeutics
TCRT
$4.66M
$933K 0.26%
+1,000
New +$980K
INSM icon
46
PUT
Insmed
INSM
$21.3B
$858K 0.24%
+50,000
New +$854K
ARAV
47
PUT
DELISTED
Aravive, Inc. Common Stock
ARAV
$857K 0.24%
8,183
– –
OMER icon
48
PUT
Omeros
OMER
$909M
$796K 0.22%
+40,000
New +$698K
ACOR
49
PUT
DELISTED
Acorda Therapeutics
ACOR
$591K 0.17%
+250
New +$495K
GOGO icon
50
PUT
Gogo Inc
GOGO
$606M
$577K 0.16%
+50,000
New +$608K
1
2
3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Acuta Capital Partners held 90 positions worth $357M, down 15% from $422M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Acuta Capital Partners withdrew a net $58.5M in Q2 2017, closing 30 positions and reducing 14 holdings. Its most notable exit was Oxford Immunotec Global PLC Ordinary Shares, an estimated $5.98M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Technology.

Against the trend, Acuta Capital Partners opened a new position in Kite Pharma, Inc. worth $7.78M.

  • Acuta Capital Partners's largest Q2 2017 buy was Kite Pharma, Inc.: 75,000 shares worth $7.78M.
  • Acuta Capital Partners added most to Ascendis Pharma A/S in Q2 2017, an estimated $9.89M increase.
  • Acuta Capital Partners's biggest Q2 2017 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $9.77M.
  • Acuta Capital Partners fully exited Oxford Immunotec Global PLC Ordinary Shares in Q2 2017, selling an estimated $5.98M.
  • Acuta Capital Partners's ten largest holdings make up 66% of its $357M portfolio in Q2 2017.
  • Acuta Capital Partners opened 23 new positions and closed 30 in Q2 2017.
  • Acuta Capital Partners's portfolio value fell 15% quarter-over-quarter to $357M.

Based on Acuta Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.